Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke

NCT07392450 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT07392450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07392450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Recruiting
Start date
May 17, 2026
Completion date
December 6, 2027
Enrollment
222 (estimated)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke